Usefulness of Transient and Persistent No Reflow to Predict Adverse Clinical Outcomes Following Percutaneous Coronary Intervention
William Chan, Dion Stub, David J Clark, Andrew E Ajani, Nick Andrianopoulos, Angela L Brennan, Gishel New, Alexander Black, James A Shaw, Christopher M Reid, Anthony M Dart, Stephen J Duffy
AMERICAN JOURNAL OF CARDIOLOGY | EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC | Published : 2012
The Melbourne Interventional Group acknowledges unrestricted educational grant funding from Abbot Vascular, AstraZeneca, Biotronik, Boston-Scientific, Bristol-Myers Squibb, CSL, Johnson and Johnson, Medtronic, Pfizer, Schering-Plough, Sanofi-Aventis, and Servier.Dr. Chan is supported by scholarships from the National Health and Medical Research Council (NHMRC) of Australia, Canberra, ACT, Australia and GlaxoSmithKline. Dr. Duffy's work is supported by an NHMRC of Australia Program Grant. The work of Dr. Reid, Ms. Brennan, and Dr. Andrianopoulos is supported by an NHMRC of Australia Program Grant.